Big Phar­ma-backed Sit­ryx locks an ad­di­tion­al $39M in a Se­ries A raise to ad­vance its im­munometa­bol­ic pipeline

Sit­ryx Ther­a­peu­tics has raised an ad­di­tion­al £32 mil­lion ($39 mil­lion) in a fol­low-on to its 2018 Se­ries A to help push its im­munometa­bol­ic pipeline in­to the clin­ic.

New in­vestor Ox­ford Sci­ence En­ter­pris­es (OSE) joins the fray with Big Phar­ma back­ers GSK and Eli Lil­ly, as well as Sofinno­va Part­ners, SV Health In­vestors and Long­wood Fund. The Ox­ford, UK-based com­pa­ny made its de­but in 2018 with a $30 mil­lion Se­ries A, bring­ing its to­tal fundrais­ing to more than $75 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER